People: Alimera Sciences Inc (ALIM.W)

Summary

Name	Age	Since	Current Position
Philip Tracy	70	2004	Independent Chairman of the Board
C. Daniel Myers	58		President, Chief Executive Officer, Director
Richard Eiswirth	44	2010	Chief Financial Officer, Chief Operating Officer
Kenneth Green	54	2007	Senior Vice President, Chief Scientific Officer
David Holland	49	2010	Senior Vice President - Sales and Marketing
Philip Ashman		2012	Senior Vice President, European Managing Director
Susan Caballa	68	2004	Senior Vice President - Regulatory and Medical Affairs
Garheng Kong		2012	Director
Glen Bradley	69	2011	Independent Director
Mark Brooks		2004	Independent Director
Brian Halak	41	2004	Independent Director
James Largent	62	2011	Independent Director
Peter Pizzo	46	2010	Independent Director
Calvin Roberts	60	2003	Independent Director
John Mills			IR Contact

» Insider Trading

Biographies

Name	Description
Philip Tracy	Mr. Philip R.Tracy is Independent Chairman of the Board of Alimera Sciences Inc. Since 1998, Mr. Tracy has served as a Venture Partner of Intersouth Partners. He is also counsel to the Raleigh, North Carolina law firm Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. Previously, Mr. Tracy was employed by Burroughs Wellcome Co. from 1974 to 1995 and served as President and Chief Executive Officer from 1989 to 1995. Mr. Tracy holds an L.L.B. from George Washington University and a B.A. from the University of Nebraska.
C. Daniel Myers	Mr. C. Daniel Myers is President, Chief Executive Officer and Director of Alimera Sciences, Inc. He is one of co-founders and has served as Chief Executive Officer and as a director since the founding of Company in 2003. Before founding Company, Mr. Myers was an initial employee of Novartis Ophthalmics (formerly CIBA Vision Ophthalmics) and served as its Vice President of Sales and Marketing from 1991 to 1997 and as President from 1997 to 2003. Mr. Myers holds a B.S. in Industrial Management from Georgia Institute of Technology.
Richard Eiswirth	Mr. Richard S. Eiswirth, Jr., is Chief Financial Officer and Chief Operating Officer of Alimera Sciences, Inc. He has served as Chief Financial Officer of Company since October 2005 and as Chief Operating Officer since August 2010. From 2003 to 2005, Mr. Eiswirth served as founding partner of Brand Ignition Group, engaged in consumer products acquisition activities. From 2002 to 2005, Mr. Eiswirth served as President of Black River Holdings, Inc., a financial consultancy he founded in 2002. Mr. Eiswirth served as Chief Financial Officer and Senior Executive Vice President of Netzee, Inc., a provider of Internet banking solutions to community banks from 1999 to 2002. Mr. Eiswirth held various positions with Arthur Andersen, where he began his career, from 1991 to 1999. Mr. Eiswirth currently serves as chairman, audit committee chairman and member of the compensation committee of Jones Soda Co., a Seattle, Washington based beverage company, and previously served as director and audit committee chairman of Color Imaging, Inc., a Norcross, Georgia based manufacturer of printer and copier supplies. Mr. Eiswirth was previously a Certified Public Accountant in Georgia. Mr. Eiswirth holds a Bachelor’s in accounting from Wake Forest University.
Kenneth Green	Dr. Kenneth Green, Ph.D., is Senior Vice President and Chief Scientific Officer of Alimera Sciences, Inc. He joined the company in 2004 as Vice President of Scientific Affairs, and has served as the Senior Vice President and Chief Scientific Officer of Company since January 2007. Prior to joining the company, Dr. Green served as the V.P. Global Head of Clinical Sciences at Novartis Ophthalmics. He has managed ophthalmic clinical development organizations at Storz Ophthalmics, Bausch & Lomb and CIBA Vision. He started his career in the pharmaceutical industry in 1984, as a basic research scientist in drug discovery at Lederle Laboratories, and has since held positions in many areas of drug development. Dr. Green holds a B.A. in Chemistry from Southern Illinois University and a Ph.D. in Organic Chemistry from Ohio State University.
David Holland	Mr. David R. Holland is Senior Vice President - Sales and Marketing of Alimera Sciences, Inc. He is one of co-founders and served as the Vice President of Marketing since the founding of Company in 2003 through August 2010 when he was appointed the Senior Vice President of Sales and Marketing. Prior to founding Company, Mr. Holland served as the Vice President of Marketing of Novartis Ophthalmics from 1998 to 2003. In 1997, Mr. Holland served as Global Head of the Lens Business at CIBA Vision and in 1996, Global Head of the Lens Care Business of CIBA Vision. From 1992 to 1995, Mr. Holland served as the Director of Marketing for CIBA Vision Ophthalmics. From 1989 to 1991, Mr. Holland served as New Products Manager for CIBA Vision. From 1985 to 1989, Mr. Holland served as a Brand Assistant and Assistant Brand Manager of Procter and Gamble. Mr. Holland holds an A.B. in Politics from Princeton University.
Philip Ashman	Dr. Philip Ashman, Ph.D., has been appointed as Senior Vice President, European Managing Director of Alimera Sciences, Inc., effective 14 November 2012. Dr. Ashman brings to Alimera more than 20 years of experience in all aspects of pharmaceutical management. During his career, he has held numerous leadership roles, including serving as vice president at Bayer, responsible for setting strategy and early preparations for specialty medicines. He also served at Bayer as Regional Business Unit Head (Europe) in Oncology, responsible for the delivery of oncology sales and profitability targets in Europe, Canada, the Middle East and Africa. Most recently, he has been responsible for leadership of the market access strategy in the U.K. for Bayer, covering numerous therapy areas including ophthalmology. Dr. Ashman holds a doctorate in biochemistry from the University of London: Royal Holloway and Bedford, U.K., and a Bachelor of Science degree in biochemistry from the University College London, U.K.
Susan Caballa	Ms. Susan Caballa is Senior Vice President - Regulatory and Medical Affairs of Alimera Sciences, Inc. Prior to joining the company, Ms. Caballa served as the Vice President of Regulatory and Medical Affairs at Novartis Ophthalmics from 1999 to 2004. Ms. Caballa also held various regulatory management positions with the following companies engaged in the development and marketing of ophthalmic products: Allergan, Inc. (1983-1987), Iolab Corporation, a J&J Company (1987-1994) and Alcon Laboratories, Inc. (1994-1999). Ms. Caballa holds a B.S. in Chemistry and a Masters in Chemistry from the University of Santo Tomas and University of the Philippines.
Garheng Kong	Dr. Garheng Kong, M.D., PhD., is appointed as the Director of Alimera Sciences, Inc. Dr. Kong has been a general partner at Sofinnova, a venture firm focused on life sciences, since 2010. From 2000 to 2010, he was at Intersouth Partners, a venture capital firm, most recently as a general partner, where he was a founding investor or board member for various life sciences ventures, several of which were acquired by pharmaceutical companies. Dr. Kong has served on the board of directors of Cempra, Inc. since September 2006 and as chairman of its board since November 2008. Dr. Kong has served on the board of directors of SARcode BioScience, Inc., a private biopharmaceutical company, since 2011 and on the board of Histogenics Corporation, a private biotechnology company, since 2012 where he also serves as the chairman of the board. Dr. Kong holds a B.S. in chemical engineering and biological sciences from Stanford University. He holds an M.D., Ph.D. in biomedical engineering and M.B.A. from Duke University.
Glen Bradley	Dr. Glen Bradley, Ph.D., M.B.A., is Independent Director of Alimera Sciences, Inc. Dr Bradley served as the Chief Executive Officer of CIBA Vision Corporation, the eye care unit of Novartis, A.G., or CIBA Vision, from 1990 to January 2003. Since 2003, Dr Bradley has acted as a consultant to various medical device and ophthalmic drug companies. Dr. Bradley served in the positions of President and CEO from 1986 to 1989 for CIBA Vision, the United States operations of the CIBA Vision Group. Prior to CIBA Vision, he served in senior management positions in the Agricultural, Plastics & Additives and Electronic Equipment Groups of CIBA-Geigy Corporation. Dr. Bradley has been Chairman of the Board of Directors at REFOCUS Group Inc., since March 2003. He serves as a Director of Intuity Medical, Inc. He has previously held board positions with Spectra Physics, Summit Technology, Biofisica, AerovectRx, e-Dr and Biocure. He served as Chairman of the Contact Lens Institute. Dr. Bradley holds a bachelor’s degree in chemical engineering from Mississippi State University, a Ph.D. in chemical engineering from Louisiana State University, an MBA in business and finance from the University of Connecticut and is a graduate of the Advanced Management Program at Harvard Business School.
Mark Brooks	Mr. Mark J. Brooks is Independent Director of Alimera Sciences, Inc. Since its formation in January 2007, Mr. Brooks has served as a Managing Director of Scale Venture Partners. Prior to joining Scale Venture Partners, from 1995 Mr. Brooks worked for Bank of America Ventures, ultimately serving as a Managing Director. Mr. Brooks also serves on the Board of Directors of IPC The Hospitalist Company, Inc., a publicly traded provider of hospitalist services, and also serves on the Board of four privately held companies: National Healing Corporation, LivHome, Inc., Spinal Kinetics, Inc. and Oraya Therapeutics, Inc. Mr. Brooks holds an M.B.A. from the Wharton School at the University of Pennsylvania and a B.A. in Economics from Dartmouth College.
Brian Halak	Dr. Brian K. Halak, Ph.D., is Independent Director of Alimera Sciences, Inc. Dr. Halak joined Domain Associates, L.L.C. in 2001 and has served as a Partner of Domain Associates, L.L.C. since 2006. Prior to joining Domain Associates, L.L.C., Dr. Halak served as an analyst of Advanced Technology Ventures from 2000 to 2001. From 1993 to 1995, Dr. Halak has served as an analyst of Wilkerson Group. Dr. Halak holds a Doctorate in Immunology from Thomas Jefferson University and a B.S. in Engineering from the University of Pennsylvania.
James Largent	Mr. James R. Largent is Independent Director of Alimera Sciences, Inc. Mr. Largent has worked within the medical industry. He most recently served as a medical and pharmaceutical consultant, including work with U.S. ophthalmic device company, Eyeonics Inc. While there, he led the lobbying effort that resulted in the 2005 landmark decision by the Centers for Medicare & Medicaid Services (CMS) to allow for patient shared billing for premium presbyopia-correcting intraocular lenses. Also in his role as a consultant, he assisted a multinational pharmaceutical and medical device company in the evaluation of strategic targets. Prior to this, Mr. Largent served in various senior management positions at Allergan, Inc., including as vice president of strategic planning where he fostered licensing deals to build product pipelines. Earlier in his career, he was vice president of strategic marketing at Allergan Medical Optics, Inc. Mr. Largent also held positions of increasing responsibility in the marketing and sales departments at Allergan and Pharmacia Ophthalmics. In addition to serving on Alimera’s Board, Mr. Largent is on the board of directors of Tear Science, Inc., a privately held developer of diagnostic and therapeutic devices for the treatment of patients with dry eye disease. Mr. Largent earned a B.A. in chemistry and an M.B.A., both from the University of California, Irvine.
Peter Pizzo	Mr. Peter J. Pizzo, III, is Independent Director of Alimera Sciences Inc. Since its formation in 2005, Mr. Pizzo has served as the Vice President, Finance and Chief Financial Officer of Carticept Medical, Inc., a private orthopedic medical device company, which he co-founded. From 2002 until its sale in 2005, Mr. Pizzo served as the Vice President, Finance and Chief Financial Officer of Proxima Therapeutics, Inc., a private medical device company that developed and marketed local radiation delivery systems for the treatment of solid cancerous tumors. From 1996 to 2001, Mr. Pizzo worked for Serologicals Corporation, a publicly traded global provider of biological products to life science companies, ultimately serving as Vice President of Finance and Chief Financial Officer. From 1995 to 1996, Mr. Pizzo served as Vice President of Administration and Controller of ValueMark Healthcare Systems, Inc., a privately held owner-operator of psychiatric hospitals. From 1992 until its sale in 1995, Mr. Pizzo served in various senior financial positions at Hallmark Healthcare Corporation, a publicly traded hospital management company, most recently as Treasurer. Mr. Pizzo holds a Bachelor of Science with Special Attainments in Commerce from Washington and Lee University.
Calvin Roberts	Dr. Calvin W. Roberts, M.D., is Independent Director of Alimera Sciences, Inc. Dr. Roberts currently serves as the Chief Medical Officer of Bausch + Lomb. Since 1982, Dr. Roberts has served as a Clinical Professor of Ophthalmology at Weill Medical College of Cornell University. From 1989 to 2010, Dr. Roberts also served as a consultant to Allergan, Inc., Johnson & Johnson and Novartis. Dr. Roberts holds an A.B. from Princeton University and an M.D. from the College of Physicians and Surgeons of Columbia University. Dr. Roberts completed his internship and ophthalmology residency at Columbia Presbyterian Hospital in New York and completed cornea fellowships at Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute in Boston.
John Mills

Basic Compensation

Name	Fiscal Year Total
Philip Tracy	--
C. Daniel Myers	492,557
Richard Eiswirth	358,993
Kenneth Green	333,975
David Holland	325,548
Philip Ashman	--
Susan Caballa	291,412
Garheng Kong	--
Glen Bradley	--
Mark Brooks	--
Brian Halak	--
James Largent	--
Peter Pizzo	--
Calvin Roberts	--
John Mills	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Philip Tracy	0	0
C. Daniel Myers	55,147	349,081
Richard Eiswirth	0	0
Kenneth Green	21,969	146,533
David Holland	0	0
Philip Ashman	0	0
Susan Caballa	0	0
Garheng Kong	0	0
Glen Bradley	0	0
Mark Brooks	0	0
Brian Halak	0	0
James Largent	0	0
Peter Pizzo	0	0
Calvin Roberts	0	0
John Mills	0	0

Insider Trading

Name	Shares Traded	Price
HOLLAND DAVID R	30,000	$4.13
DP VI ASSOCIATES L P	232	$4.50
DOMAIN PARTNERS VI L P	21,276	$4.50
DOMAIN PARTNERS VI L P	22,966	$4.70
DP VI ASSOCIATES L P	251	$4.70
BRADLEY C GLENN	10,047	$1.42
EISWIRTH RICHARD S JR	5,000	$1.44
PIZZO PETER J III	5,000	$1.44
MYERS CHARLES DANIEL	7,700	$1.95
ROBERTS CALVIN W	75,620	$0.00
ROBERTS CALVIN W	75,621	$0.00
ROBERTS CALVIN W	75,620	$0.00
ROBERTS CALVIN W	226,861	$0.00
MYERS CHARLES DANIEL	5,950	$2.52
MYERS CHARLES DANIEL	4,000	$0.00
MYERS CHARLES DANIEL	5,900	$2.52
MYERS CHARLES DANIEL	6,350	$2.36
MYERS CHARLES DANIEL	6,388	$2.28
GREEN KENNETH	3,612	$2.28
HOLLAND DAVID R	3,630	$2.28
MYERS CHARLES DANIEL	6,745	$2.22
EISWIRTH RICHARD S JR	4,463	$2.28
HOLLAND DAVID R	11,187	$0.00
EISWIRTH RICHARD S JR	13,753	$0.00
GREEN KENNETH	11,132	$0.00

» Full list on Insider Trading

People: Alimera Sciences Inc (ALIM.W)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: